Journals / Van Tıp Dergisi / 2022 / Cilt: 29 - Sayı: 3

COVID-19 Course in Connective Tissue Disease-Related Interstitial Lung Disease Patients

Bağ Dokusu İlişkili İntertisyel Akciğer Hastalarında COVID-19 Hastalık Seyri

Pages
332–336
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Decreased forced vital capacity is a poor prognostic risk factor

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Coronovirus 2019 (COVID-19) infection has spread rapidly, causing a worldwide pandemic.
📊
Key Findings & Data:In studies on which patients are more associated with a worse prognosis, it has been associated with increased mortality in patients with lung disease.
💡
Conclusion & Impact:Decreased forced vital capacity is a poor prognostic risk factor
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: Coronovirus 2019 (COVID-19) infection has spread rapidly, causing a worldwide pandemic. Although a good clinical course ranging from asymptomatic carriage to a simple flu infection is encountered in most patients, pneumonia and even multi-organ failure and mortality can be seen in some patients. In studies on which patients are more associated with a worse prognosis, it has been associated with increased mortality in patients with lung disease. In this study, it was aimed to show the mortality rate and possible prognostic factors associated with COVID-19 in patients with interstitial lung disease due to connective tissue disease (CTD-ILD). Materials and Methods: In a tertiary referral centre, patients with previously diagnosed CTD-ILD were retrospectively reviewed. Between 1st April 2020 to 1st April 2021 patient data related to ILD disease, COVID-19 infection and mortality were obtained from electronic records retrospectively. The primary outcome was death on day 30 of COVID-19 infection Results: There were 271patients diagnosed with CTD-ILD. 74 patients had COVID-19 infection, which was confirmed by polymerase chain reaction. 29 patients were dead during the followed-up period of whom 13 patients had COVID-19 infection-related mortality (17.5% vs 8.1%, p:0.045). COVID infection related to mortality was more frequently seen in patients with decreased forced vital capacity , smoking history, extended disease and rheumatoid arthritis. On multivariate regression analysis, only decreased forced vital capacity were related to poor outcomes. Conclusion: COVID-19 infection is related to increased risk of mortality in CTD-ILD patients. Decreased forced vital capacity is a poor prognostic risk factor

Özet

Amaç: Coronovirüs 2019 (COVID-19) enfeksiyonu, hızlı bir şekilde yayılarak Dünya genelinde bir pandemiye yol açmıştır. Asemptomatik taşıyıcılıktan basit gribal bir enfeksiyona uzanan iyi seyirli kliniğe çoğu hastada rastlansa da bazı hastalarda pnömoni hatta çoklu organ yetmezliği ve mortalite görülebilmektedir. Hangi hastaların kötü prognozla daha ilişkili olduğu ile ilgili yapılan çalışmalarda, akciğer hastalığı olan hastalarda artan mortalite ile ilişkilendirilmiştir. Bu çalışmada, bağ dokusu hastalığına bağlı interstisyel akciğer hastalığı (BDHİAH) gelişmiş hastalarda, COVID-19 ile ilişkili mortalite oranı ve olası prognostik faktörlerin gösterilmesi amaçlandı. Gereç ve Yöntem: Üçüncü basamak bir sevk merkezinde, daha önce BDH-İAH tanısı almış hastalar geriye dönük olarak incelendi. 1 Nisan 2020 ile 1 Nisan 2021 arasında İAH hastalığı, COVID-19 enfeksiyonu ve mortalite ile ilgili hasta verileri elektronik kayıtlardan elde edilmiştir. Birincil sonlanım noktası COVID-19 enfeksiyonunun 30. gününde ölüm oranlarıydı. Bulgular: BDH-İAH tanısı konan 271 hasta mevcuttu. 74 hastada polimeraz zincir reaksiyonu ile doğrulanan COVID-19 enfeksiyonu vardı. Takip süresinde 29 hasta vefat etti ve bunların 13'ünde COVID-19 enfeksiyonuna bağlı mortalite görüldü (%17,5'e karşı %8,1, p:0,045). COVID -19 ilişkili mortalite azalmış bazal zorlu vital kapasite, sigara kullanma öyküsü, yaygın İAH ve romatoid artriti olan hastalarda daha sık görüldü. Çok değişkenli regresyon analizinde sadece azalmış bazal zorlu vital kapasite testleri kötü sonuçla ilişkiliydi. Sonuç: COVID-19 enfeksiyonu, BDH-İAH hastalarında artan mortalite riski ile ilişkilidir. Azalmış zorlu vital kapasite kötü bir prognostik risk faktörüdür.

🔖

Cite This Article

SATIŞ, H., ÜNSAL, Y., TUFAN, A. (2022). COVID-19 Course in Connective Tissue Disease-Related Interstitial Lung Disease Patients. Van Tıp Dergisi, Cilt: 29 - Sayı: 3, 332–336. https://ajindex.com/articles/645870

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun 2020;109:102433
  2. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci 2020;50(Si-1):620-632
  3. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou Cq, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708-1720
  4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. J Am Med Assoc 2020;323(11):1061- 9
  5. Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and metaanalysis. J Med Virol. 2020;92(10):1875- 1883
  6. Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, J Am Med Assoc March 23- May 12, 2020. 2020;180(12):1576-86
  7. Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, et al. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. Am J Respir Crit Care Med. 2020;202(12):1656-1665
  8. Gallay L, Uzunhan Y, Borie R, Lazor R, Rigaud P, Marchand-Adam S, et al. Risk Factors for Mortality after COVID-19 in Patients with Preexisting Interstitial Lung Disease. Am J Respir Crit Care Med. 2021;203(2):245-249
  9. Esposito AJ, Menon AA, Ghosh AJ, Putman RK, Fredenburgh LE, El-Chemaly SY, et al. Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case-Control Study. Am J Respir Crit Care Med. 2020;202(12):1710-1730
  10. Santos CS, Morales CM, Álvarez ED, Castro C, Robles AL, Sandoval TP. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. J Clini Rheumatol. 2020;39(9):2789-2796
  11. Truong L, Pourzand L, Volkmann ER. Covid-19 in Patients with Connective Tissue Disease-Related Interstitial Lung Disease. J Rheumatol 2021 48 (3) 468-470
  12. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177(11):1248-1254
  13. Guiot J, Henket M, Frix A-N, Delvaux M, Denis A, Giltay L, et al. Single-center experience of patients with interstitial lung dis